Developing a synagis clinic for respiratory syncytial virus prophylaxis

MCN The American Journal of Maternal Child Nursing

Volumn 26, Issue 5, 2001, Pages 246-251

  Coffman, Sherrilyn ^a   Peck, Jacqueline ^a   Rasmussen, Carolyn Sue ^b  

^a Sierra Health Services Inc   (United States)

^b Sunrise Children's Hospital   (United States)

Author keywords

Ambulatory care; Premature chronic lung disease; Respiratory Syncytial Virus

Indexed keywords

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; PALIVIZUMAB;

ARTICLE; CASE MANAGEMENT; CHILD HEALTH CARE; HUMAN; INFANT; NEWBORN; ORGANIZATION AND MANAGEMENT; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PREMATURITY; UNITED STATES; VIRUS INFECTION;

AMBULATORY CARE FACILITIES; ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; CASE MANAGEMENT; CHILD HEALTH SERVICES; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; NEVADA; OUTCOME ASSESSMENT (HEALTH CARE); RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 0035461294     PISSN: 0361929X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005721-200109000-00006     Document Type: Article

References (11)

1. Centers for Disease Control and Prevention (CDC) (1998). Update: Respiratory syncytial virus activity - United States, 1997-98 season. MMWR Weekly, 47(48), 1043-1045.
2. Centers for Disease Control and Prevention (CDC). (2000). Respiratory syncytial virus activity - United States, 1999-2000 season. MMWR Weekly, 49(48), 1091-1093.
3. Englund, J. A. (1999). Active and passive immunization for the prevention of respiratory syncytial virus disease. University of Chicago Children's Hospital Reports on Current Concepts in the Use of Pediatric Vaccines, 2(1), 1-12.
4. Impact-RSV Study Group. (1998). Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics, 102, 531-537.
5. Kempker-Russell, M. (1999). Focus on preparation for RSV season. MCN, The American Journal of Maternal Child Nursing 24, 226-229.
6. MedImmune, Inc. (1998). Questions and answers on Synagis (Palivizumab) & respiratory Syncytial virus. Gaithersburg, MD: Author.
7. Meissner, H. C., Welliver, R. C., Chartrand, S. A., Law, B. J., Weisman, L. E. Dorkin, H. L., et al. (1999). Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: A consensus opinion. The Pediatric Infectious Disease Journal, 18, 223-231.
8. Nafstad, P., Magnus, P., & Jaakkola, J. (2000). Early respiratory infections and childhood asthma. Pediatrics, 106(3), 592.
9. Product Information. (1998). Palivizumab. Gaithersburg, MD: MedImmune, Inc.
10. Sandritter, T. L., & Kraus, D. M. (1997). Respiratory syncytial virus-immunoglobulin intravenous (RSV-IVIG) for respiratory syncytial viral infections: Part 1. Journal of Pediatric Health Care, 11, 284-293.
11. Schaffer, M., Greenspan, J., Amaya, M. A., & Vojta, D. (2000, May). Palivizumab for respiratory syncytial virus (RSV) prophylaxis of high-risk infants in a medicaid health maintenance organization (HMO). Paper presented at the Pediatric Academic Societies and the American Academy of Pediatrics Year 2000 Joint Meeting, Boston, MA.